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Abstract
Background: Elevated low density lipoprotein (LDL) and lipoprotein(a) are independent risk factors for the development of
atherosclerosis. Using a proteomic approach we aimed to determine early changes in arterial protein expression in
transgenic mice containing both human LDL and lipoprotein(a) in circulation.
Methods and Results: Plasma lipid analyses showed the lipoprotein(a) transgenic mice had significantly higher lipid levels
than wildtype, including a much increased LDL and high density lipoprotein (HDL) cholesterol. Analysis of aortae from
lipoprotein(a) mice showed lipoprotein(a) accumulation but no lipid accumulation or foam cells, leaving the arteries
essentially atherosclerosis free. Using two-dimensional gel electrophoresis and mass spectrometry, we identified 34 arterial
proteins with significantly altered abundance (P,0.05) in lipoprotein(a) transgenic mice compared to wildtype including 17
that showed a $2 fold difference. Some proteins of interest showed a similarly altered abundance at the transcript level.
These changes collectively indicated an initial metabolic response that included a down regulation in energy, redox and
lipid metabolism proteins and changes in structural proteins at a stage when atherosclerosis had not yet developed.
Conclusions: Our study shows that human LDL and lipoprotein(a) promote changes in the expression of a unique set of
arterial proteins which may be early indicators of the metabolic disturbances preceding atherosclerosis.
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Introduction
A number of transgenic mouse models have been generated to
study atherosclerosis [1,2,3,4]. The apoE deficient mouse
(apoE
–/–) is the most widely utilized of these due to its ability to
rapidly form spontaneous lesions that resemble those in humans
[2,3]. This model has been deployed in genetic, drug and
nutrition-based studies to identify molecules and factors that
modify the progression of the disease [5]. In the majority of these
studies, lesion area and composition have been analysed as main
endpoints. Few studies have attempted to investigate the complex
regulation underlying the development of atherosclerosis, partic-
ularly at the early stage of the disease before lesions become
apparent. Quantitative proteomic studies can achieve this by
detecting dynamic changes in cellular proteins to reveal molecular
mechanisms of disease [6,7,8]. One study has investigated the
proteomic changes in apoE
–/– mice at various stages of lesion
development and found that a redox imbalance and impaired
energy metabolism preceded lesion development [9]. The elevated
levels of remnant lipoproteins in the apoE
–/– animals likely drove
these changes. However, whether the same changes occur in
mouse models with a different pattern of lipid perturbation is
unknown.
Large clinical trials have established that elevated low density
lipoprotein (LDL) levels are a common risk factor for the
development of atherosclerosis [10,11,12]. Furthermore, humans
contain an additional lipoprotein in their plasma which is not
found in mice, namely lipoprotein(a) (Lp(a)), a unique lipoprotein
consisting of an LDL covalently bound to apolipoprotein(a)
(apo(a)) [13]. Studies to determine if Lp(a) is a risk factor for
atherosclerosis have been somewhat controversial but meta-
analysis studies confirm it as a modest risk factor [14,15] and
recent large trials report major risk under conditions of extreme
Lp(a) levels [16,17]. Interestingly, some clinical trials show a J-
shaped curve for coronary artery disease (CAD) risk [18]
indicating that at low levels Lp(a) may protect against the
development of CAD, but beyond a threshold level, promotes
the disease [19].
A mouse model for Lp(a) was initially developed by expressing a
human apo(a) transgene [20,21], however, these animals did not
contain bona fide Lp(a) in circulation [21]. Subsequently, the
human apo(a) mice were bred to human apoB transgenic mice to
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LDL and Lp(a) in circulation [4,22]. With respect to the impact of
Lp(a) on atherosclerosis in these animals, there has been mixed
results. Callow et al. [23] observed that the Lp(a) mice developed
atherosclerotic lesions more so than human apoB mice suggesting
that the presence of Lp(a) enhanced atherosclerosis development.
Mancini et al. [24] also found lesion development in Lp(a) mice,
although unlike Callow, did not see any accentuation in lesion
development by Lp(a). Both studies utilized a high fat diet to
enhance atherosclerosis development. While these studies show the
combination of elevated LDL and Lp(a) can be atherogenic in the
setting of a high fat diet, the underlying response of arterial tissue
to this particular lipoprotein profile is unknown.
Here we applied a proteomic approach to the artery of the
human Lp(a) mouse to identify early changes that occur in
response to the perturbed lipoprotein profile present in these
animals without the influence of a high fat diet.
Materials and Methods
Ethics Statement
All animal protocols were reviewed and approved by the
University of Otago Animal Ethics Committee (AEC protocol No.
25/03).
Mice
Wildtype C57BL/6 mice were purchased from Jackson
Laboratories (Bar Harbor, ME). Lp(a) transgenic mice were
generated by breeding transgenic mice expressing a human apo(a)
cDNA encoding seventeen KIV domains [21] backcrossed onto a
C57BL/6 background with human apoB100 transgenic mice [4]
backcrossed onto a C57BL/6 background. The C57BL/6
background of the Lp(a) transgenic mice was confirmed by
genotyping of C57BL/6 strain specific markers by Saturn Biotech
Limited (Perth, Australia). Mice were fed a chow diet (Ruakura 86
(5.2% fat) Sharps, Carterton, New Zealand) and housed in a
specific pathogen-free animal facility with a 12-hour light/dark
cycle at 22uC. Blood and aortae were harvested from 20 Lp(a)
transgenic and 20 wildtype female mice at 30 weeks of age.
Histological Assessment of the Aorta
For histological analysis, the aortae from eight Lp(a) transgenic
and eight wildtype mice were perfusion fixed in situ with
phosphate-buffered formalin, removed and further fixed in
formalin. The aortic arch from the aortic root to the first
intercostal branch was processed for histology. Arteries were
embedded in paraffin and 4 mm serial sections taken through the
longitudinal axis of the aortic arch. Sections were stained with
either Verhoeff’s elastic stain and Curtis’ modified van Gieson
stain or haematoxylin and eosin. Sections were also immuno-
stained with a polyclonal rabbit anti-human Lp(a) antibody (Dako
A/S, Glostrup, Denmark) followed by a goat anti-rabbit hrp-
conjugated antibody (Pierce, Rockford, IL).
Plasma lipid analysis
Whole blood was collected via cardiac puncture before
perfusion of aortae and placed in EDTA microtubes. Plasma
was isolated and stored at 280uC. Plasma levels of cholesterol and
triglyceride were measured using enzymatic reagents from Roche
Diagnostics (Mannheim, Germany) and phospholipids measured
using an enzymatic reagent from Wako (Osaka, Japan). Plasma
levels of human Lp(a) and human apoB were measured using
apo(a)-specific and apoB-specific enzyme-linked immunosorbent
assays (ELISAs) as previously described [25]. Immunoblot analysis
of Lp(a) mouse plasma separated by SDS PAGE under
nonreducing conditions was performed to investigate the relative
amounts of apoB and apo(a) bound in the Lp(a) complex as
opposed to unbound. The distribution of lipids amongst plasma
lipoproteins was analysed by separation of pooled plasma samples
by gel permeation chromatography (n=4 samples per pool) on a
Superose 6HR 10/30 column from GE Healthcare Bio-Sciences
(Uppsala, Sweden). Separated fractions were measured for
cholesterol and triglycerides by enzymatic assay (Roche).
Aorta lipid analysis
Lipids were extracted from a pool of six aortic sections adjacent to
that used for proteomics with a modification of the method by
Bartels et al. [26]. Tissue was homogenized in phosphate-buffered
saline (PBS) containing a protease inhibitor cocktail (Roche) and
lipids were extracted with chloroform/methanol and evaporated
under nitrogen gas. Lipids were resuspended in isopropanol
containing 1% Triton X-100. Cholesterol, triglyceride and phos-
pholipid levels in the lipid extracts were measured using enzymatic
reagents. A fluorometric thiobarbituric acid reactive substances
(TBARS) assay [27] was used to measure the concentration of
aldehydes as a measure of oxidized lipids in the lipid extracts.
Proteomic Analysis
For proteomic analysis, the aortae from 12 Lp(a) transgenic and
12 wildtype mice were perfused in situ with PBS and removed. The
aortic arch from the aortic root to the first intercostal branch pair
was sectioned and this and the remaining artery rinsed thoroughly
in PBS and immediately frozen in liquid nitrogen. The aortic
arches were used for proteomic analysis by two-dimensional
polyacrylamide gel electrophoresis (2-D PAGE) and the remaining
sections for lipid analysis. Detailed methodology of the proteomic
analysis and mass spectrometry (Text S1) used to identify
differences in relative protein abundance between the Lp(a) and
wildtype mice is available online as supporting information.
Quantitative RT-PCR analysis
Quantitative RT-PCR was used to quantify the level of mRNA
transcript for proteins of interest showing a $2 fold difference in
protein abundance. Total RNA was isolated from 6 pooled aorta
samples from either wildtype or Lp(a) mice using Trizol
(Invitrogen; Carlsbad, CA). One mg of RNA was reverse
transcribed to cDNA using Transcriptor Reverse Transcriptase
and random pd(N)6 primers (Roche). Quantitative PCR was
performed on a LightCycler 480 instrument (Roche) using the
SYBR Green I detection system. The primer sequences for each
transcript are available from the authors on request. The cDNA
was amplified with the following conditions: 95uC for 5 min, 50
cycles of 95uC for 5 sec, 59uC for 5 sec and 72uC for 8 sec. Melt
curve analyses were performed at the end of cycling. The level of
each transcript was quantified relative to 18S rRNA using the Fit
Points and 2nd Derivative Maximum calculation for each sample.
Statistics and Bioinformatics
Statistical analyses were performed using GraphPad Prism
(GraphPad, San Diego, CA). A non-paired Student’s t-test was
used to test for significant differences in mean lipid levels and the
mean normalized spot volumes obtained from 2-D PAGE analysis
of the Lp(a) transgenic versus wildtype mice. A difference with
P,0.05 was considered significant. The AmiGO search tool was
used to screen the gene ontology (GO) database to annotate the
functional relevance of proteins identified as being significantly
different in relative abundance between Lp(a) and wildtype mice.
Proteomics of Lipoprotein(a) Mice
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Elevated lipids in plasma but not in the arteries of Lp(a)
transgenic mice
Lp(a) transgenic mice had significantly higher concentrations of
cholesterol, triglyceride and phospholipids in plasma than wildtype
mice (99 versus 40 mg/dL cholesterol (P,0.001), 98 versus 65
mg/dL triglyceride (P,0.05) and 116 versus 45 mg/dL phospho-
lipids (P,0.001) (Figure 1A). Separation of the plasma lipoproteins
(Figure 1B) showed the Lp(a) transgenic mice to have elevated
LDL and HDL with the cholesterol relatively evenly distributed
between the two. In the wildtype mice the cholesterol was largely
all in the HDL. Human apoB and apo(a) concentrations in the
Lp(a) transgenic mice were 32.263.4 and 12.560.9 mg/dL
respectively which were comparable to that previously reported for
these mice on a chow diet [4,24]. Based on molar concentrations,
there was a three-fold excess of apoB to apo(a) in the plasma of the
Lp(a) mice. Indeed, a large excess of unbound apoB (LDL) to
bound apoB [Lp(a)] was observed in the plasma of the Lp(a) mice
after separation by nondenaturing SDS PAGE and immunoblot
analysis (Figure 2A). However, these immunoblots are highly likely
to under-represent the Lp(a) band due to a lower transfer
efficiency of the larger Lp(a) complex and the likelihood that
epitopes on apoB may be masked by the bound apo(a) which
would reduce Lp(a) immunoreactivity compared to LDL. Notably,
all of the apo(a) in the plasma of the Lp(a) mice was bound to
human apoB in the form of Lp(a) (Figure 2B).
The elevated levels of plasma lipids in the Lp(a) mice were not
associated with lipid accumulation in the arteries. Indeed,
cholesterol and triglyceride concentrations in the aorta of Lp(a)
transgenic mice were significantly reduced compared to wildtype
mice (Figure 3A). Interestingly, the Lp(a) transgenic mice had a
significantly elevated concentration of thiobarbituric acid-reactive
substances (TBARS) in the aorta compared to wildtype suggesting
an accumulation of aldehydes from lipid oxidation (Figure 3B).
Histological assessment of arteries showed no
atherosclerosis
Histological analysis showed no evidence of atherosclerosis in
the arteries of Lp(a) transgenic mice or wildtype mice including no
Figure 1. Plasma lipids in wildtype and Lp(a) mice. A, Lp(a) mice
(n=12) had significantly higher concentrations of total cholesterol (TC),
triglyceride (TG) and phospholipids (PL) in plasma than wildtype mice
(n=12). Data is represented as mean concentration 6 SEM.
*P,0.05,
***P,0.001 versus wildtype. B, Plasma lipoproteins were separated by
gel permeation chromatography and the cholesterol content of each
fraction measured. Lp(a) mice had elevated LDL and HDL with the
cholesterol relatively evenly distributed between the two. In the
wildtype mice the cholesterol was largely all in the HDL.
doi:10.1371/journal.pone.0030383.g001
Figure 2. Representative immunoblot of Lp(a) mouse plasma. Plasma was separated by SDS PAGE under nonreducing conditions and subject
to immunoblot analysis. A, An anti-human apoB-specific antibody was used to detect both LDL and Lp(a), indicating an excess of unbound apoB
(LDL) to bound apoB [Lp(a)]. B, An anti-human apo(a)-specific antibody was used to detect Lp(a) and free apo(a), which showed all apo(a) was bound
to human apoB in the form of Lp(a). Plasma from human apoB and human apo(a) only mice were included as controls.
doi:10.1371/journal.pone.0030383.g002
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aortic sinus (Figures 4C and D). The Lp(a) mice did show staining
with an Lp(a)-specific antibody indicating retention of Lp(a) in the
arterial wall (Figure 4F. The wildtype mice were negative for Lp(a)
staining (Figure 4E).
Proteomics assessment
Changes in the proteome of the aortic arch between Lp(a) and
wildtype mice was assessed by 2-D PAGE. Figure 5A shows a
representative 2-D PAGE image from the 12 pooled aortic arches
of Lp(a) mice. Approximately 500 protein spots were detected
across all gels. A comparative analysis of equivalent spots between
the averaged gels of the Lp(a) and wildtype mice identified 34 spots
with significantly different intensities (12 increased and 22
decreased) including 17 proteins showing a $2 fold difference.
Figure 5B shows a close up of the majority of protein spots
showing a $2 fold difference. The 34 spots (numbered 1-34 in
Figure 5A) were excised and subject to mass spectrometry-based
protein identification. Identified proteins are listed in Table S1 and
further information of protein identifications is given in Table S2.
Proteins are grouped as functionally categorized by GO analysis.
In a few cases, multiple different spots of the same protein were
identified indicative of post- translational modifications to the
protein. These all showed the same direction of change. Major
classes of proteins identified as being altered in the Lp(a) mice were
those involved in energy metabolism, lipid synthesis, oxidative
stress response and structural remodelling.
Impaired energy metabolism
Several energy metabolism enzymes were significantly de-
creased by $ 2 fold (Table S1). These included pyruvate kinase
which catalyses one of the two ATP-generating steps in glycolysis
and a subunit of the pyruvate dehydrogenase complex (dihydro-
lipoyllysine dehydrogenase), which converts pyruvate to acetyl
CoA in the initial irreversible step feeding into the tricarboxylic
acid (TCA) cycle. A decrease in glucose-6-phosphate dehydroge-
nase, a key regulatory enzyme for the pentose phosphate pathway
and NADPH production was evident. Two TCA cycle enzymes
were decreased, including two subunits of oxoglutarate dehydro-
genase (dihydrolipoyllysine dehydrogenase and dihydrolipoyllysine
succinyltransferase) and a subunit of the isocitrate dehydrogenase
enzyme. Both enzymes catalyse the generation of NADH.
Two subunits required for the electron transfer from FADH
into complex II of the electron transport chain (electron transfer
flavoprotein dehydrogenase and electron transfer flavoprotein)
were significantly decreased, as was a subunit of complex III
(cytochrome b-cl subunit 1).
Downregulation in lipid trafficking and synthesis
There was a major reduction in glucose-3-phosphate dehydro-
genase, a key enzyme for lipid synthesis that converts dihydroxy-
acetone to glycerol-3 phosphate for triglyceride and phospholipid
synthesis (Table S1). A major reduction in fatty acid binding
protein 4 (Fabp4), a protein responsible for intracellular trafficking
of lipids for lipid synthesis, b-oxidation and cellular signalling was
also evident along with a decrease in the long chain specific acyl-
CoA dehydrogenase required for b-oxidation of long chain fatty
acids to yield FADH.
Oxidative stress response
As well as alterations in energy metabolism proteins involved in
NADH and NADPH production which could be expected to alter
the redox status of arterial cells, a number of proteins involved in
oxidative stress responses were altered including the heat shock
proteins, Hsp60 and 70, carbonic anhydrase 3 and peroxiredoxin
4, an antioxidant enzyme that reduces lipid peroxides (Table S1).
Early vascular remodelling
A number of structural proteins were $2 fold increased in the
arteries of Lp(a) mice (Table S1). These included, transgelin a
cytoskeletal protein involved in actin-binding and multiple forms
of microfibril-associated glycoprotein 4 (Mfap4), an extracellular
matrix protein known to regulate cellular adherence to elastin.
RT PCR analysis of transcript
Quantitative RT-PCR was performed to investigate if proteins of
interest showing a $2 fold change at the protein level were also
regulated at the mRNA transcript level between the Lp(a) and
wildtype mice (Figure 6). With respect to proteins involved in
NADPH/NADH generation, the glucose-6-phosphate dehydroge-
nase transcript was increased 1.7 fold, the dihydrolipopoyllysine
succinyltransferase transcript reduced 2.9 fold and the isocitrate
dehydrogenase transcript showed no significant difference in Lp(a)
mice compared to wildtype mice. With respect to lipid metabolism,
the glycerol-3-phosphate dehydrogenase and fatty acid-binding
protein 4 transcripts were both significantly decreased in Lp(a) mice
compared to wildtype (2.0 and 3.1 fold respectively). In relation to
oxidative stress, the peroxiredoxin 4 transcript was quantified and
showed a 2.2 fold increase in Lp(a) compared to wildtype mice.
Figure 3. Comparison of aorta lipids in wildtype and Lp(a)
mice. A, Total cholesterol (TC), triglyceride (TG) and phospholipids (PL)
in homogenized aorta lipid extracts (n=6). TC and TG concentrations in
the aorta of Lp(a) mice were significantly reduced compared to
wildtype mice. B, Lp(a) mice had a significantly elevated concentration
of thiobarbituric acid-reactive substances (TBARS) in the aorta
compared to wildtype suggesting an accumulation of aldehydes from
lipid oxidation. Data represented as mean concentration 6 SEM.
**P,0.01 versus wildtype.
doi:10.1371/journal.pone.0030383.g003
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The aim of our study was to investigate the response of the
mouse artery to the atherogenic lipoprotein profile of elevated
human LDL and Lp(a). The study presents the first proteomic
assessment of a mouse model containing a lipoprotein profile that
more closely resembles that in humans with a focus on early
changes within the artery and without the influence of diet. The
results indicate changes in energy, lipid and redox metabolism
with some vascular remodelling collectively pointing to an early
response to the elevated lipid profile before any atherosclerotic
lesions are evident. The Lp(a) mice did accumulate Lp(a) and lipid
oxidation products in their arteries both of which are likely to have
contributed to this response. Our results are in line with a previous
Figure 4. Representative histological analysis of aortae from wildtype and Lp(a) mice. Aortic arches and sinuses of wildtype and Lp(a)
mice (n=8) were stained with haematoxylin and eosin (A and B) or Verhoeff’s elastic stain and Curtis’ modified van Gieson stain (C and D), which
stained the elastic laminar (black), smooth muscle (brown), and collagen-rich fibrous tissue (red/pink). There was no evidence of atherosclerosis in the
arteries of Lp(a) mice or wildtype mice, including no evidence of foam cells in the aortic arch or aortic sinus. Aortic arches were also immunostained
with an anti-human Lp(a) antibody (brown) and counterstained with haematoxylin (blue). E, The wildtype mice were negative for Lp(a). F, The Lp(a)
mice showed staining with the Lp(a)-specific antibody, indicating retention of Lp(a) in the arterial wall. Scale bar represents 100 mm.
doi:10.1371/journal.pone.0030383.g004
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–/– mice with no apparent lesions
which also revealed alterations in energy, lipid and redox
metabolism [9], although the subset of proteins identified were
different. This may indicate that different lipoprotein profiles
promote different responses in the arterial wall with respect to
changes in protein expression.
Energy and Redox Metabolism
A downregulation in energy metabolism was evident with a
number of enzyme subunits from the glycolysis, TCA cycle and
electron transport pathways showing $2 fold decrease in Lp(a)
mice. Collectively these changes would be expected to impair
vascular ATP and NADH/NADPH production. Three enzymes
involved in NADH generation in the mitochondria, dihydroli-
poyllysine dehydrogenase, dihydolipoyllysine succinyltransferase,
both part of the oxoglutarate dehydrogenase complex, and
isocitrate dehydrogenase, were downregulated at the protein level.
Dihydrolipoyllysine succinyltransferase also showed a significant
(2.9 fold) downregulation at the transcript level. Two of only three
enzymes capable of generating NADPH i.e. glucose-6-phosphate
dehydrogenase and isocitrate dehydrogenase were significantly
downregulated at the protein level, although neither showed a
reduced transcript level suggesting a regulation at a post-
transcriptional level. A reduction in NADPH could induce
oxidative stress by decreasing the regeneration of major cellular
antioxidants, glutathione and thioredoxin, which work in con-
junction with glutathione peroxidase and peroxiredoxins respec-
tively to reduce lipid peroxides [28]. Indeed, there was an increase
in the concentration of oxidised lipids in the Lp(a) mice along with
an upregulation of oxidative stress proteins including peroxir-
edoxin 4 which was increased at both the protein and mRNA
level. An oxidative stress response does occur in mouse models of
atherosclerosis as seen in the proteomic study of apoE
–/– mice [9]
and a recent microarray study of LDLR
–/– mice [29]. Both studies
showed that a decreased ability to mount an antioxidant response
with age was associated with the onset of atherosclerosis.
Lipid Metabolism
The downregulation in glycolysis might be expected to impact
on lipid metabolism by ultimately reducing the amount of acetyl
CoA available for fatty acid synthesis. Moreover, there was a
significant decrease at both protein and transcript level in Fabp4, a
fatty acid binding protein that traffics fatty acids for synthesis and
glycerol-3 phosphate dehydrogenase, a key regulatory enzyme for
triglyceride synthesis. Indeed, Fabp4 was the most significantly
downregulated protein in the Lp(a) mice at both the protein (6.3
fold) and transcript level (3.1 fold). All of these changes would be
expected to reduce arterial triglyceride synthesis. The downreg-
ulation of enzymes producing NADPH would be expected to
reduce cholesterol synthesis which utilizes significant quantities of
NADPH. The proteomic data supports the lipid data which
showed a significant decrease in both triglyceride and cholesterol
levels in the arteries of Lp(a) mice, despite a significant increase in
plasma lipids and arterial Lp(a) accumulation.
Figure 5. Representative 2-D PAGE image of proteins expressed in aortae of Lp(a) mice. A, Pooled aortic arch protein extracts (n=12)
were separated by 2-D PAGE in triplicate. Comparative analysis of equivalent spots between the averaged gels of the Lp(a) and wildtype mice
identified 34 spots with significantly different intensities. Protein spots showing a significant difference in relative abundance (P,0.05) are indicated
by numbers and their abbreviated protein names are listed in Table S1. B, Close-up images of selected protein spots showing $2 fold difference
between wildtype and Lp(a) mice. In a few cases, multiple different spots of the same protein were identified indicative of post translational
modifications to the protein. Proteins identified with multiple spots are denoted with (*).
doi:10.1371/journal.pone.0030383.g005
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change at the protein level were also regulated at the mRNA transcript level between the Lp(a) and wildtype mice. Total RNA was isolated from aorta
samples (n=6) of wildtype and Lp(a) mice. RNA was reverse transcribed to cDNA and quantitative PCR for transcripts of interest relative to 18S rRNA
was performed. Glucose-6-phosphate dehydrogenase (G6pdx) and peroxiredoxin 4 (Prdx4) transcripts were increased in Lp(a) mice compared to
wildtype. Dihydrolipopoyllysine succinyltransferase (Dlst), Glycerol-3-phosphate dehydrogenase (Gpd1) and fatty acid-binding protein 4 (Fabp4)
transcripts were decreased in Lp(a) mice compared to wildtype. Isocitrate dehydrogenase (Idh3a) transcript showed no significant difference in Lp(a)
mice compared to wildtype mice. Results are presented as relative levels of transcript normalized to wildtype.
***P,0.001 versus wildtype.
doi:10.1371/journal.pone.0030383.g006
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Fabp4 deficient mice on an apoE
–/– background show a striking
protection from atherosclerosis [30]. Fabp4 is a negative regulator
of LXR-mediated cholesterol efflux by ABCA1 in macrophages
and coordinates the inflammatory activity of macrophages [31]. A
reduction in Fabp4 would be expected to enhance ABCA1-
mediated efflux of cholesterol from the artery and suppress
inflammation. The lack of foam cells present in the arteries of
Lp(a) transgenic mice suggests that the smooth muscle cell (SMC),
was the likely source of Fabp4 protein in the artery. The
expression of Fabp4 has been reported in SMCs [32]. To
investigate whether other cell types in the Lp(a) mice showed
similar changes in Fabp4, we investigated the levels of Fabp4
transcript in the liver and showed a 2 fold decrease (Figure S1). It
would be of interest to establish whether Fabp4 levels are altered
in the adipocytes and macrophage populations of the Lp(a) mice.
Interestingly, the lipid data showed a significant increase in HDL
in the Lp(a) animals which could be connected with the reduction
in Fabp4 in liver cells. The increased in HDL would be expected
to provide increased anti-inflammatory protection for the arteries
[33] which may explain in part why these animals have not yet
developed atherosclerosis.
Structural remodeling
Also of interest was a 2.2 fold increase in the cytoskeletal
protein, transgelin and a 2-fold increase in the cell adhesion
protein, Mfap4. Interestingly, transgelin, an actin-binding protein
abundant in smooth muscle cells is downregulated in atheroscle-
rosis and a deficiency accelerates atherosclerosis in apoE
–/– mice
[34]. A recent paper suggests that the protection afforded by
transgelin is largely due to its anti-inflammatory properties [35].
Mfap4 is a bridging protein that connects elastin to aortic cells and
seems to play an important role in maintaining vascular integrity.
The increases in transgelin and Mfap4 would be expected to be
protective by reducing inflammation and maintaining the integrity
and contractility of the vasculature in the face of an early stress
response.
Study Limitations
Our study shows that human LDL and moderate Lp(a) levels
promote an early metabolic response in the arteries of mice
independent of lesion development. A longer term study would be
required to extend this observation as the response is likely to
change with age. Indeed, older apo(a) transgenic animals do
develop atherosclerosis on a chow diet [36].
Our study has not shown that Lp(a) is specifically responsible for
the proteomic changes seen in our mice since the mice also had
elevated LDL levels as a result of the human apoB transgene.
Although the main aim of our study was to investigate the
combined effect of elevated LDL and the presence of Lp(a), it
would be of interest to compare human apoB mice with human
Lp(a) mice to dissect the response of the artery to human LDL
versus Lp(a). It would also be of interest to compare the response
of the Lp(a) transgenic mice used here to those with higher Lp(a)
levels as generated by Schneider et al. [37]. Higher levels of Lp(a)
would be expected to promote a greater level of oxidative stress
which may promote a different response to that seen here.
Our study does not discriminate between different arterial cell
types, which is a common restriction for many proteomic studies
particularly in mice [9]. This potentially limits the interpretation
with respect to matching identified proteins to arterial cell types.
However, for the most part, particularly as the arteries were
atherosclerosis free, the prominent cell type expected here is the
SMC. This was supported by our proteomic data, which featured
a number of SMC-specific structural proteins.
Summary
Here we show that human LDL and Lp(a) promote an initial
response in mouse arteries free from atherosclerosis involving
changes in energy, redox and lipid metabolism and structural
remodeling. We have identified a set of proteins underlying this
response some of which have independently been shown to be
atheroprotective and others which may be early indicators of
atherosclerosis development.
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presented as relative levels of transcript normalized to wildtype.
**P,0.01 versus wildtype.
(TIFF)
Table S1 Proteins showing significant (P,0.05) differential
expression in the aortic arches of Lp(a) versus wildtype mice on
a normal chow diet (DOC). * Fold change between Lp(a) versus
wildtype mice. Positive number indicates an increased expression
in the Lp(a) mice. Negative number indicates a decreased
expression in the Lp(a) mice.
(DOC)
Table S2 Proteins identified by MALDI-TOF MS/MS from the
2D-PAGE of aortic arches from wildtype versus Lp(a) mice
(DOC).
1 Raw spot volumes were log transformed and normalized
by zero-centering through median subtraction.
(DOC)
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